{"version":"1.0","type":"link","title":"Cost-effectiveness analysis of tepotinib vs capmatinib as subsequent therapy in MET exon 14-mutated non-small-cell lung cancer.","author_name":"Liu M 외","author_url":"https://prs-insight.online/author/Liu%20M","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/93444","thumbnail_width":1200,"thumbnail_height":630}